Minetto, P.; Candoni, A.; Guolo, F.; Clavio, M.; Zannier, M.E.; Miglino, M.; Dubbini, M.V.; Carminati, E.; Sicuranza, A.; Ciofini, S.;
et al. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers 2021, 13, 34.
https://doi.org/10.3390/cancers13010034
AMA Style
Minetto P, Candoni A, Guolo F, Clavio M, Zannier ME, Miglino M, Dubbini MV, Carminati E, Sicuranza A, Ciofini S,
et al. Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers. 2021; 13(1):34.
https://doi.org/10.3390/cancers13010034
Chicago/Turabian Style
Minetto, Paola, Anna Candoni, Fabio Guolo, Marino Clavio, Maria Elena Zannier, Maurizio Miglino, Maria Vittoria Dubbini, Enrico Carminati, Anna Sicuranza, Sara Ciofini,
and et al. 2021. "Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden" Cancers 13, no. 1: 34.
https://doi.org/10.3390/cancers13010034
APA Style
Minetto, P., Candoni, A., Guolo, F., Clavio, M., Zannier, M. E., Miglino, M., Dubbini, M. V., Carminati, E., Sicuranza, A., Ciofini, S., Colombo, N., Pugliese, G., Marcolin, R., Santoni, A., Ballerini, F., Lanino, L., Cea, M., Gobbi, M., Bocchia, M.,
... Lemoli, R. M.
(2021). Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. Cancers, 13(1), 34.
https://doi.org/10.3390/cancers13010034